Marker Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $6.90 million
- Book Value:
- Revenue TTM:
- $9.01 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Marker Therapeutics Inc had its IPO on 2014-03-25 under the ticker symbol MRKR.
The company operates in the Healthcare sector and Biotechnology industry. Marker Therapeutics Inc has a staff strength of 67 employees.
Shares of Marker Therapeutics Inc opened at $0.76 at the start of the last trading session i.e. 2023-03-31.
The stocks traded within a range of $0.67 - $0.77, and closed at $0.71.
This is a -8.97% slip from the previous day's closing price.
A total volume of 114,554 shares were traded at the close of the day’s session.
In the last one week, shares of Marker Therapeutics Inc have slipped by -24.47%.
Marker Therapeutics Inc's Key Ratios
Marker Therapeutics Inc has a market cap of $6.90 million, indicating a price to book ratio of 1.1336 and a price to sales ratio of 3.5926.
In the last 12-months Marker Therapeutics Inc’s revenue was $9.01 million with a gross profit of $-17125779 and an EBITDA of $-27156676. The EBITDA ratio measures Marker Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Marker Therapeutics Inc’s operating margin was -332.23% while its return on assets stood at -36.5% with a return of equity of -94.14%.
In Q4, Marker Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 166.5%.
Marker Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-3.73 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Marker Therapeutics Inc’s profitability.
Marker Therapeutics Inc stock is trading at a EV to sales ratio of 3.6408 and a EV to EBITDA ratio of -0.4721. Its price to sales ratio in the trailing 12-months stood at 3.5926.
Marker Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $34.42 million
- Total Liabilities
- $7.78 million
- Operating Cash Flow
- Capital Expenditure
- $1.36 million
- Dividend Payout Ratio
Marker Therapeutics Inc ended 2023 with $34.42 million in total assets and $0 in total liabilities. Its intangible assets were valued at $34.42 million while shareholder equity stood at $19.60 million.
Marker Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $7.78 million in other current liabilities, 8406.00 in common stock, $-428049049.00 in retained earnings and $0 in goodwill. Its cash balance stood at $11.78 million and cash and short-term investments were $11.78 million. The company’s total short-term debt was $577,198 while long-term debt stood at $0.
Marker Therapeutics Inc’s total current assets stands at $16.62 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $2.40 million compared to accounts payable of $0 and inventory worth $0.
In 2023, Marker Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $1.36 million.
Comparatively, Marker Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Marker Therapeutics Inc stock is currently trading at $0.71 per share. It touched a 52-week high of $6.6 and a 52-week low of $6.6. Analysts tracking the stock have a 12-month average target price of $40.
Its 50-day moving average was $2.17 and 200-day moving average was $3.16 The short ratio stood at 3.97 indicating a short percent outstanding of 0%.
Around 1281.8% of the company’s stock are held by insiders while 2286.6% are held by institutions.
Frequently Asked Questions About Marker Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company’s MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing MT-401, which is in Phase 2 clinical trial for the treatment of post-transplant AML; MT-401-OTS for the treatment of AML; and MT-601 for the treatment of pancreatic cancer and lymphoma. Marker Therapeutics was founded in 1999 and is headquartered in Houston, Texas.